Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

Video

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Prasad S. Adusumilli, MD, FACS, deputy chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center, discusses the current role of chimeric antigen receptor (CAR) T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Investigators are currently translating data from preclinical trials to determine the potential role of CAR T cells in solid tumors. Unlike in the hematologic space, there are several hurdles to overcome in solid tumors that are specific to the solid tumor microenvironment, Adusumilli says.

At this time, investigators are focusing on how to overcome each of the hurdles to determine the role of CAR T-cell therapy in the treatment landscape of solid tumors.

For example, one hurdle to overcome is that T cells are unable to enter the tumor with solid tumors, especially when the T cells are administered intravenously, Adusumilli explains.

<<< 2020 International Congress on Hematologic Malignancies

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.